Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced ...
J.P. Morgan releases its quarterly look-ahead days before the entire biopharma industry descends on San Francisco for the ...
The J.P. Morgan Healthcare Conference attracts thousands of attendees each year from the provider, insurance, digital health ...
J.P. Morgan analyst Doug Anmuth said he sees room for Alphabet, Google’s parent, to gain ground on a variety of fronts, ...
The drug industry is facing one of the largest patent cliffs in recent history. Will that mean dealmaking at the annual J.P.
M&A didn’t return as hoped for in 2024. The biopharma industry is heading into the J.P. Morgan Healthcare Conference next ...
Like many other major companies, especially those in finance, JPMorgan is making the push for more in-person work.
J.P. Morgan Asset Management’s Michael Cembalest calls them “Alchemists” — the Trump White House nominees who are looking to ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Excelerate Energy downgraded at J.P. Morgan, which sees the stock slowing after a strong 2024 relative to other liquefied ...
J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback